LTRN Lantern Pharma Inc.

17.77
+0.9  (+5%)
Previous Close 16.87
Open 17.86
52 Week Low 10.4
52 Week High 24.84
Market Cap $198,470,731
Shares 11,168,865
Float 7,253,103
Enterprise Value $170,516,926
Volume 306,278
Av. Daily Volume 212,258
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
LP-300
Non-small cell lung cancer (NSCLC)
Phase 2
Phase 2
Phase 2 trial planned.
LP-100
Hormone-refractory prostate cancer (MHRPC)
Phase 2
Phase 2
Phase 2 trial ongoing.

Latest News

  1. DALLAS, Jan. 20, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ:LTRN), a clinical-stage biopharma company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform cancer drug development and identify patients who will benefit from its targeted oncology therapeutics, today announced the closing of its previously announced public offering of 4,928,571 shares of its common stock at a public offering price of $14.00 per share, which includes 642,856 shares sold upon full exercise of the underwriter's option to purchase additional common shares. The gross proceeds from the offering, including the exercise of the over-allotment option, were $68,999,994, before deducting underwriting discounts, commissions and offering expenses…

    DALLAS, Jan. 20, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ:LTRN), a clinical-stage biopharma company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform cancer drug development and identify patients who will benefit from its targeted oncology therapeutics, today announced the closing of its previously announced public offering of 4,928,571 shares of its common stock at a public offering price of $14.00 per share, which includes 642,856 shares sold upon full exercise of the underwriter's option to purchase additional common shares. The gross proceeds from the offering, including the exercise of the over-allotment option, were $68,999,994, before deducting underwriting discounts, commissions and offering expenses.

    ThinkEquity, a division of Fordham Financial Management, Inc., acted as sole book-running manager for the offering. Colliers Securities LLC acted as co-manager for the offering.

    A registration statement on Form S-1 (File No. 333-251992) relating to the shares was filed with the Securities and Exchange Commission and became effective on January 14, 2021, and a related registration statement on Form S-1 (File No. 333-252116) was filed pursuant to Rule 462(b) of the Securities Act of 1933, as amended, in connection with the upsizing of the offering. This offering was made only by means of a prospectus. Copies of the final prospectus may be obtained from ThinkEquity, a division of Fordham Financial Management, Inc., 17 State Street, 22nd Floor, New York, New York 10004, by telephone at (877) 436-3673, by email at .

    This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

    About Lantern Pharma

    Lantern Pharma (LTRN) is a clinical-stage biopharmaceutical company innovating the repurposing, revitalization and development of precision therapeutics in oncology. We leverage advances in machine learning, genomics, and artificial intelligence by using a proprietary A.I. platform to discover biomarker signatures that help identify patients more likely to respond to our pipeline of cancer therapeutics. Lantern's focus is to improve the outcome for patients by leveraging our technology to uncover, rescue and develop abandoned or failed drugs. Our current pipeline of three drugs, with two programs in clinical stages and two in preclinical, focuses on cancers that have unique and unmet clinical needs with a clearly defined patient population. We believe that the use of machine learning, genomics and computational methods can help accelerate the revitalization, refocusing and development of small molecule-based therapies. By targeting drugs to patients whose genomic profile identifies them as having the highest probability of benefiting from the drug, this approach represents the potential to deliver best-in-class outcomes. Our team seeks out experienced industry partners, world-class scientific advisors, and innovative clinical-regulatory approaches to assist in delivering cancer therapies to patients as quickly and efficiently as possible. For more information, please visit the company's website at www.lanternpharma.com or follow the company on Twitter @lanternpharma. 

    Forward Looking Statements

    This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Lantern Pharma's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled "Risk Factors" in the final prospectus related to the public offering filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Lantern Pharma undertakes no duty to update such information except as required under applicable law.

    Contact:

    Lantern Pharma

    Investors & Media

    email:

    Twitter: @lanternpharma

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/lantern-pharma-announces-closing-of-public-offering-of-69-million-usd-and-full-exercise-of-underwriters-over-allotment-option-301211989.html

    SOURCE Lantern Pharma

    View Full Article Hide Full Article
  2. DALLAS, Jan. 14, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ:LTRN), a clinical-stage biopharma company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform cancer drug development and identify patients who will benefit from its targeted oncology therapeutics, today announced the pricing of a public offering of 4,285,715 shares of its common stock at a public offering price of $14.00 per share, for gross proceeds of $60 million, before deducting underwriting discounts and offering expenses. In addition, Lantern Pharma has granted the underwriters a 45-day option to purchase up to an additional 642,856 shares of common stock at the public offering price, less the underwriting discount, to cover over-allotments. All…

    DALLAS, Jan. 14, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ:LTRN), a clinical-stage biopharma company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform cancer drug development and identify patients who will benefit from its targeted oncology therapeutics, today announced the pricing of a public offering of 4,285,715 shares of its common stock at a public offering price of $14.00 per share, for gross proceeds of $60 million, before deducting underwriting discounts and offering expenses. In addition, Lantern Pharma has granted the underwriters a 45-day option to purchase up to an additional 642,856 shares of common stock at the public offering price, less the underwriting discount, to cover over-allotments. All of the shares of common stock are being offered by Lantern Pharma.

    The offering is expected to close on January 20, 2021, subject to satisfaction of customary closing conditions.

    ThinkEquity, a division of Fordham Financial Management, Inc., is acting as sole book-running manager for the offering.  Colliers Securities LLC is acting as co-manager for the offering.

    A registration statement on Form S-1 (File No. 333-251992) relating to the shares was filed with the Securities and Exchange Commission ("SEC") and became effective on January 14, 2021. This offering is being made only by means of a prospectus. Copies of the final prospectus, when available, may be obtained from ThinkEquity, a division of Fordham Financial Management, Inc., 17 State Street, 22nd Floor, New York, New York 10004, by telephone at (877) 436-3673, by email at   The final prospectus will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov.

    This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    About Lantern Pharma

    Lantern Pharma (LTRN) is a clinical-stage biopharmaceutical company innovating the repurposing, revitalization and development of precision therapeutics in oncology. We leverage advances in machine learning, genomics, and artificial intelligence by using a proprietary A.I. platform to discover biomarker signatures that help identify patients more likely to respond to our pipeline of cancer therapeutics. Lantern's focus is to improve the outcome for patients by leveraging our technology to uncover, rescue and develop abandoned or failed drugs. Our current pipeline of three drugs, with two programs in clinical stages and two in preclinical, focuses on cancers that have unique and unmet clinical needs with a clearly defined patient population. We believe that the use of machine learning, genomics and computational methods can help accelerate the revitalization, refocusing and development of small molecule-based therapies. By targeting drugs to patients whose genomic profile identifies them as having the highest probability of benefiting from the drug, this approach represents the potential to deliver best-in-class outcomes. Our team seeks out experienced industry partners, world-class scientific advisors, and innovative clinical-regulatory approaches to assist in delivering cancer therapies to patients as quickly and efficiently as possible. For more information, please visit the company's website at www.lanternpharma.com or follow the company on Twitter @lanternpharma.

    Forward Looking Statements

    This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Lantern Pharma's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled "Risk Factors" in the final prospectus related to the public offering filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Lantern Pharma undertakes no duty to update such information except as required under applicable law.

    Contact:

    Lantern Pharma

    Investors & Media

    email:

    Twitter: @lanternpharma

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/lantern-pharma-announces-pricing-of-60-million-public-offering-301209029.html

    SOURCE Lantern Pharma

    View Full Article Hide Full Article
  3. DALLAS and LA JOLLA, Calif., Jan. 4, 2021 /PRNewswire/ -- Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform cancer drug development and identify patients who will benefit from its targeted oncology therapeutics, today announced that it will be launching the development of its ADC (Antibody Drug Conjugate) program through an evaluation and potential development agreement with Califia Pharma along with other key internal development and computational initiatives. Lantern will potentially leverage the patent-protected linker library, conjugation processes and payloads, including its own DNA damage causing compounds, LP-100 and LP-184, for development…

    DALLAS and LA JOLLA, Calif., Jan. 4, 2021 /PRNewswire/ -- Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform cancer drug development and identify patients who will benefit from its targeted oncology therapeutics, today announced that it will be launching the development of its ADC (Antibody Drug Conjugate) program through an evaluation and potential development agreement with Califia Pharma along with other key internal development and computational initiatives. Lantern will potentially leverage the patent-protected linker library, conjugation processes and payloads, including its own DNA damage causing compounds, LP-100 and LP-184, for development as ADC-based therapies for a range of solid tumors and blood cancers. In addition, Lantern intends to utilize its proprietary A.I. platform, known as RADR®, to help determine the cancer types, targets, and cancer biomarker signatures believed most likely to respond to and benefit from this ADC approach. According to industry analysts, the global antibody drug conjugate cancer therapy market is expected to exceed $10 billion USD by 2026, and $15 billion USD by 2030, driven by innovations in protein targeting, linker technologies and conjugation processes. 

    ADCs bring together the ability to target specific antibodies on specific cancer cells and then link that antibody targeting capability to delivering specific potent molecules or toxic payloads to the targeted cancer cell. ADCs are an emerging class of highly potent drugs that have seen five FDA approvals over the last two years. 

    "At Lantern we are focused on uncovering and accelerating new advances that can make a meaningful impact on personalizing cancer treatment and that can leverage our A.I. and data driven model for precision cancer drug development. The Califia portfolio of technologies and library of linkers has been meaningfully progressed with a specific focus on the class of drugs represented by LP-100 and LP-184. We believe that this optimization coupled with our identification of cancer sub-types should enable us to target very specific cancers quickly, creating the potential to enter into clinical trials at a speed that we believe has not been achieved in the ADC category," said Panna Sharma, CEO of Lantern Pharma.  ADCs can use the specificity of antibodies and antigens to focus cytotoxic small molecules on target cells "precisely" and then kill them based on releasing the "payload" by designing and controlling the linker element. "Pioneering development by Califia has yielded novel linkers and chemistries that we believe have significantly improved the therapeutic index of specific DNA damage compounds and alkylating agents in early pre-clinical studies, and have also minimized the manufacturing steps involved in conjugation of the ADC structure," added Panna Sharma

    "Working closely with innovators and world-leading drug developers is an essential part of our strategy to leverage and develop new platforms that can transform the timeline and effectiveness of cancer drug development.  By implementing ADC approaches, we aim to offer cancer patients an additional, highly-targeted platform that can make meaningful contributions in advancing the personalization of treatment, while also benefitting from synergies with our A.I. drug development platform," continued Panna Sharma.

    The ADC program will begin immediately and initially focus on evaluating Califia's novel, patented linker technologies with DNA damaging small molecules, including LP-100 and LP-184, in select solid tumors. Lantern also expects to use RADR® to guide the selection and prioritization of certain tumors and cancer subtypes and also to uncover cancer sub-types where there is significant unmet patient need, especially in rare tumors and orphan indications where there have not been recent meaningful improvements in the standard of care. The ADC development program is at the forefront of translational cancer medicine and will be optimizing target indications and design during 2021, with the intent to launch IND and clinical programs in 2022. Subject to positive results of the evaluation and early development process, Lantern expects to enter into a license(s) that cover the intended target(s), payload(s) and linker(s) to be brought into the clinical development process. This rapid approach is intended to be done in collaboration with leading cancer research centers and will attempt to also implement the use of precision medicine tools, such as biomarker driven targeting and analysis, companion diagnostics, and large-scale analytics to fully leverage the precision power of ADCs.

    About Lantern Pharma

    Lantern Pharma (LTRN) is a clinical-stage biopharmaceutical company innovating the repurposing, revitalization and development of precision therapeutics in oncology. We leverage advances in machine learning, genomics, and artificial intelligence by using a proprietary A.I. platform to discover biomarker signatures that help identify patients more likely to respond to our pipeline of cancer therapeutics. Lantern's focus is to improve the outcome for patients by leveraging our technology to uncover, rescue and develop abandoned or failed drugs. Our current pipeline of three drugs, with two programs in clinical stages and two in preclinical, focuses on cancers that have unique and unmet clinical needs with a clearly defined patient population. We believe that the use of machine learning, genomics and computational methods can help accelerate the revitalization, refocusing and development of small molecule-based therapies. By targeting drugs to patients whose genomic profile identifies them as having the highest probability of benefiting from the drug, this approach represents the potential to deliver best-in-class outcomes. Our team seeks out experienced industry partners, world-class scientific advisors, and innovative clinical-regulatory approaches to assist in delivering cancer therapies to patients as quickly and efficiently as possible. For more information, please visit the company's website at www.lanternpharma.com or follow the company on Twitter @lanternpharma.

    Contact:

    Marek Ciszewski, J.D.

    Director, Investor Relations

    628-777-3167

    Forward-looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of our drug candidates and antibody drug conjugate (ADC) development program; estimates regarding the development timing for our drug candidates and ADC development program; our strategic plans to expand the number of data points that our RADR® platform can access and analyze; our research and development efforts of our internal drug discovery programs and the utilization of our RADR® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements to the effect that Lantern Pharma Inc. or our management "believes", "expects", "anticipates", "estimates", "plans" (and similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the risk that our antibody drug conjugate (ADC) development program may not be successful; (ii) the risk that our evaluation of linkers, drug payloads and conjugation processes from Califia may not yield meaningful results; (iii) the risk that we may not license any linkers, drug payloads and conjugation processes from Califia; (iv) the risk that we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for any ADC product candidate; (v) no drug product based on our proprietary RADR A.I. platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (vi) those other factors set forth in the Risk Factors section in our final prospectus, dated June 10, 2020, for our initial public offering, on file with the Securities and Exchange Commission. You may access our June 10, 2020 final prospectus under the investor SEC filings tab of our website at www.lanternpharma.com or on the SEC's website at www.sec.gov. Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/lantern-pharma-announces-launch-of-antibody-drug-conjugate-adc-program-to-target-solid-tumors--blood-cancers-through-agreement-with-califia-pharma-301200136.html

    SOURCE Lantern Pharma

    View Full Article Hide Full Article
  4. DALLAS, Dec. 17, 2020 /PRNewswire/ -- Lantern Pharma (NASDAQ:LTRN), a clinical-stage biopharma company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform cancer drug development and identify patients who will benefit from its targeted oncology therapeutics, today announced a collaboration and research agreement with the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and Kennedy Krieger Institute. The collaboration will focus on the further development of Lantern's LP-184 in glioblastoma multiforme (GBM). Based in Baltimore, Johns Hopkins is a leading research center for brain cancers and one of the largest brain tumor treatment and research centers in the world with a focus on treating an extremely large…

    DALLAS, Dec. 17, 2020 /PRNewswire/ -- Lantern Pharma (NASDAQ:LTRN), a clinical-stage biopharma company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform cancer drug development and identify patients who will benefit from its targeted oncology therapeutics, today announced a collaboration and research agreement with the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and Kennedy Krieger Institute. The collaboration will focus on the further development of Lantern's LP-184 in glioblastoma multiforme (GBM). Based in Baltimore, Johns Hopkins is a leading research center for brain cancers and one of the largest brain tumor treatment and research centers in the world with a focus on treating an extremely large number of patients affected by all types of brain tumors.

    The collaboration will focus on advancing the targeted use of LP-184 in defined subtypes of GBM and clarifying the most promising clinical applications for the drug candidate. The goal of the collaboration is to develop a clinically ready program that has characterized the drug candidate with the most biologically relevant and robust genomic or biomarker signature. By having a gene signature that can be used in identifying patients that have the potential for the highest response, Lantern can potentially accelerate future clinical trials and shorten the time to achieving patient benefit for GBM patients.

    The research program is at the forefront of translational cancer medicine and will use patient-derived cancer cells that are studied using physiologically relevant in vitro and in vivo models. This innovative approach allows researchers to more precisely understand the biology of what actually happens inside the cancer tumor, which will more accurately establish the precise biomarker signatures and help provide data-driven insight into additional mechanisms that can be leveraged in the fight against brain cancer.

    "Collaborations with world-leading cancer centers are an essential part of our strategy to rapidly advance the insights driving our therapeutic programs and grow the power of our RADR® A.I. platform by adding millions of new, unique, and proprietary data points in areas of high unmet need in cancer," said Panna Sharma, CEO of Lantern Pharma. "This relationship with Johns Hopkins is expected to allow us to use state-of-the-art models and biological methods to add more physiologically relevant data and insights into the mechanisms of LP-184, and further shape our algorithms for how our drug candidates interact with specific brain cancer subtypes. We believe the unique insights we gain will equip Lantern with critical advantages in our aim of accelerating LP-184's path to clinical trials and ultimately commercialization while saving millions of dollars in development costs. This data-enabled and biomarker-based approach has the potential to meaningfully bend the cost curve of cancer drug development and help bring personalized cancer therapies to patients with reduced economic burden, and greater efficacy."

    The research will be led by John Laterra, MD, Ph.D., an internationally recognized researcher in neurology, oncology, and neuroscience. Dr. Laterra serves as the Co-Director of the Brain Cancer Program and the Director of the Division of Neuro-Oncology at Johns Hopkins School of Medicine where he specializes in investigating mechanisms of brain tumor malignancy, tumor vascular biology, and identification of new therapeutic targets in gliomas.

    LP-184 is a DNA-damaging small molecule drug candidate currently in preclinical development for certain genomically defined solid tumors, including glioblastomas. As a next-generation alkylating agent that preferentially damages DNA in cancer cells that overexpress certain biomarkers and can cross the blood-brain barrier, we believe LP-184 has the potential to be used as both monotherapy as well as a synergistic agent in combination with other drugs.

    "We are focused on finding how LP-184 can exploit certain molecular mechanisms in gliomas to offer improved disease management and survival for glioblastoma patients," said Dr. Kishor Bhatia, Chief Scientific Officer at Lantern Pharma. Dr. Bhatia continued, "We look forward to our collaboration with Johns Hopkins, the Brain Cancer Program and Dr. Laterra who is at the forefront of GBM research. His approach combines real world patient insights along with advanced methodologies and patient-derived models that can improve the quality of the insight and provide more relevant data on efficacy. We look forward to sharing these results with the broader scientific and clinical community."

    Among several objectives, the research goals are to determine whether certain genomic signatures generated with RADR®, Lantern's A.I. platform, can predict response to LP-184 and a more favorable outcome as compared to standard of care agents being used today. LP-184 has been advanced using Lantern's proprietary RADR® A.I. platform that leverages over one billion curated cancer data points, machine learning, genomics, and computational biology to accelerate the discovery of potential mechanisms of action, and biomarker signatures that correlate to drug response in cancer patients.

    Although significant recent advances have been made in the use of targeted and biomarker-based therapies in cancer, GBM remains an area that has not experienced significant improvement in patient outcomes. The overall five-year survival rate for GBM across all stages remains at only 5.5% in the US, and GBM accounts for nearly 52% of all primary brain tumors each year according to the National Cancer Institute.

    About Lantern Pharma

    Lantern Pharma (LTRN) is a clinical-stage biopharmaceutical company innovating the repurposing, revitalization and development of precision therapeutics in oncology. We leverage advances in machine learning, genomics, and artificial intelligence by using a proprietary A.I. platform to discover biomarker signatures that help identify patients more likely to respond to our pipeline of cancer therapeutics. Lantern's focus is to improve the outcome for patients by leveraging our technology to uncover, rescue and develop abandoned or failed drugs. Our current pipeline of three drugs, with two programs in clinical stages and two in preclinical, focuses on cancers that have unique and unmet clinical needs with a clearly defined patient population. We believe that the use of machine learning, genomics and computational methods can help accelerate the revitalization, refocusing and development of small molecule-based therapies. By targeting drugs to patients whose genomic profile identifies them as having the highest probability of benefiting from the drug, this approach represents the potential to deliver best-in-class outcomes. Our team seeks out experienced industry partners, world-class scientific advisors, and innovative clinical-regulatory approaches to assist in delivering cancer therapies to patients as quickly and efficiently as possible. For more information, please visit the company's website at www.lanternpharma.com or follow the company on Twitter @lanternpharma.

    Contact:

    Marek Ciszewski, J.D.

    Director, Investor Relations

    628-777-3167

    Forward-looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of our drug candidates; estimates regarding the development timing for our drug candidates; our strategic plans to expand the number of data points that our RADR® platform can access and analyze; our research and development efforts of our internal drug discovery programs and the utilization of our RADR® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements to the effect that Lantern Pharma Inc. or our management "believes", "expects", "anticipates", "estimates", "plans" (and similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the risk that results of our preclinical studies concerning GBM and blood brain barrier permeability for LP-184 may not be indicative of results obtained in future clinical trials; (ii) the risk that our LP-184 drug candidate may not advance through the preclinical development and clinical trial process on a timely basis, or at all; (iii) the risk that the results of such trials will not warrant submission for approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; (iv) the risk that the Company may not be able to successfully conclude clinical testing or obtain marketing approval for its LP-184 drug candidate, (v) no drug product based on our proprietary RADR A.I. platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (vi) those other factors set forth in the Risk Factors section in our final prospectus, dated June 10, 2020, for our initial public offering, on file with the Securities and Exchange Commission. You may access our June 10, 2020 final prospectus under the investor SEC filings tab of our website at www.lanternpharma.com or on the SEC's website at www.sec.gov. Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/lantern-pharma-announces-collaboration-with-world-leading-brain-cancer-program-at-johns-hopkins-to-further-develop-lp-184-as-therapy-for-glioblastoma-301194949.html

    SOURCE Lantern Pharma

    View Full Article Hide Full Article
  5. DALLAS, Dec. 15, 2020 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform drug discovery and development, and identify patients who will benefit from its portfolio of targeted oncology therapeutics, announced today new scientific data that substantiates blood brain barrier permeability (BBB) for its drug candidate LP-184. LP-184 is being targeted for treating Glioblastoma Multiforme (GBM), an aggressive malignant form of brain cancer that comprises about 52% of all primary malignant brain tumors according to the American Association of Neurological Surgeons.  GBM has a median survival rate of only 15 months and ranks among…

    DALLAS, Dec. 15, 2020 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform drug discovery and development, and identify patients who will benefit from its portfolio of targeted oncology therapeutics, announced today new scientific data that substantiates blood brain barrier permeability (BBB) for its drug candidate LP-184. LP-184 is being targeted for treating Glioblastoma Multiforme (GBM), an aggressive malignant form of brain cancer that comprises about 52% of all primary malignant brain tumors according to the American Association of Neurological Surgeons.  GBM has a median survival rate of only 15 months and ranks among the most aggressive of human cancers. It is considered an orphan disease for which there is no cure. The global GBM treatment market is projected to reach $3.3 billion by 2024, according to GlobalData, with the U.S. representing the largest market.

    The ability of a drug candidate to cross the blood brain barrier is of critical importance in treatment outcomes for CNS and brain cancers. Many drugs fail in clinical trials because of their low blood brain barrier permeability.  Lantern's A.I. engine along with algorithms tuned to predict BBB permeability played an important role in helping determine which CNS cancers and which genomically-defined subtypes of CNS cancer should be prioritized for development. 

    The current standard of care for GBM consists of de-bulking surgery followed by combined treatments with fractionated ionizing radiation (IR) and the DNA alkylating agent temozolomide (TMZ). The effectiveness of standard therapy with TMZ is limited because the response of GBM to TMZ is dependent upon the expression of the DNA repair enzymatic protein, O6-alkylguanine DNA alkyltransferase (MGMT).  Over the period of treatment, tumors can evolve and begin to overexpress MGMT and therefore become largely resistant to TMZ. At the stage of GBM relapse and recurrence, no effective therapy strategies currently exist. LP-184 has a different mechanism of action relative to TMZ and has not demonstrated limitations due to MGMT levels, the enzymatic protein associated with resistance to TMZ in GBM and gliomas.

    LP-184 works by causing DNA damage in cancer cells that can be repaired exclusively by the nucleotide excision repair (NER) pathway, while TMZ causes damage that can be repaired exclusively by the base excision repair pathway (BER). These approaches to killing tumor cells may be complementary and represent the potential for future combination therapy applications. Using in-silico tools, and also generating further in-vitro data from both neuronal cell-plates, and neurospheres, LP-184 demonstrated permeability that was in line with TMZ and other therapies being used in GBM today, while also demonstrating nano-molar potency.

    Panna Sharma, CEO of Lantern Pharma, stated: "This data is extremely significant as it provides evidence that opens up a range of brain cancers with high clinical need that we should pursue, and also provides evidence that our RADR® platform is working as was designed. Our mission is to transform and accelerate the cancer drug development process.  If we can compress the time to clinical trials, and de-risk LP-184, we can save years of research and millions of dollars in developing treatments for GBM and potentially other CNS and brain cancers."

    Mr. Sharma continued, "As part of our development strategy we will be providing updates on new collaborations and research studies with leading research and translational cancer centers to help us further validate our findings and guide the ideal clinical usage of the compound in GBM. Based on data from our RADR platform, the blood brain barrier profile validation, and information on the genomics that seem to drive response to LP-184 we are now targeting a broader range of central nervous system cancers, including cancers that metastasize to the brain, and pediatric brain tumors."

    About Lantern Pharma

    Lantern Pharma (LTRN) is a clinical-stage biopharmaceutical company innovating the repurposing, revitalization and development of precision therapeutics in oncology. We leverage advances in machine learning, genomics, and artificial intelligence by using a proprietary A.I. platform to discover biomarker signatures that help identify patients more likely to respond to our pipeline of cancer therapeutics. Lantern's focus is to improve the outcome for patients by leveraging our technology to uncover, rescue and develop abandoned or failed drugs. Our current pipeline of three drugs, with two programs in clinical stages and two in preclinical, focuses on cancers that have unique and unmet clinical needs with a clearly defined patient population. We believe that the use of machine learning, genomics and computational methods can help accelerate the revitalization, refocusing and development of small molecule-based therapies. By targeting drugs to patients whose genomic profile identifies them as having the highest probability of benefiting from the drug, this approach represents the potential to deliver best-in-class outcomes. Our team seeks out experienced industry partners, world-class scientific advisors, and innovative clinical-regulatory approaches to assist in delivering cancer therapies to patients as quickly and efficiently as possible. For more information, please visit the company's website at www.lanternpharma.com or follow the company on Twitter @lanternpharma.

    Contact

    Marek Ciszewski, JD

    Director, Investor Relations

    628-777-3167

    Forward-looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of our drug candidates; estimates regarding the development timing for our drug candidates; our strategic plans to expand the number of data points that our RADR® platform can access and analyze; our research and development efforts of our internal drug discovery programs and the utilization of our RADR® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development      and to identify patient populations that would likely respond to a drug candidate; estimates regarding potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements to the effect that Lantern Pharma Inc. or our management "believes", "expects", "anticipates", "estimates", "plans" (and similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the risk that results of our preclinical studies concerning blood brain barrier permeability for LP-184 may not be indicative of results obtained in future clinical trials; (ii) the risk that our LP-184 drug candidate may not advance through the preclinical development and clinical trial process on a timely basis, or at all; (iii) the risk that the results of such trials will not warrant submission for approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; (iv) the risk that the Company may not be able to successfully conclude clinical testing or obtain marketing approval for its LP-184 drug candidate, (v) no drug product based on our proprietary RADR A.I. platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (vi) those other factors set forth in the Risk Factors section in our final prospectus, dated June 10, 2020, for our initial public offering, on file with the Securities and Exchange Commission. You may access our June 10, 2020 final prospectus under the investor SEC filings tab of our website at www.lanternpharma.com or on the SEC's website at www.sec.gov. Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/lantern-pharma-announces-scientific--preclinical-data-indicating-blood-brain-barrier-permeability-for-drug-candidate-lp-184-in-glioblastoma-and-potentially-other-cns-cancers-301192777.html

    SOURCE Lantern Pharma

    View Full Article Hide Full Article
View All Lantern Pharma Inc. News